Intra-and interindividual variabilities in the pharmacokinetics of fentanyl buccal soluble film in healthy subjects: A cross-study analysis

Clinical Drug Investigation

Volumn 31, Issue 5, 2011, Pages 317-324

  Davies, Andrew ^a   Finn, Andrew ^b   Tagarro, Ignacio ^c  

^a St Lukes Surgery   (United Kingdom)

^b BioDelivery Sciences International Inc   (United States)

^c Meda Pharmaceuticals   (Spain)

Author keywords

Cancer pain; Fentanyl; pharmacokinetics; treatment

Indexed keywords

FENTANYL CITRATE;

ADULT; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CANCER PAIN; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EXPOSURE; FEMALE; FILM; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, BUCCAL; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; FENTANYL; HUMANS; MALE; SOLUBILITY; YOUNG ADULT;

EID: 79953831361     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11533540-000000000-00000     Document Type: Article

References (16)

1. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009 Apr; 13 (4): 331-8
2. Zeppetella G. Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care 2009 Mar; 3 (1): 1-6
3. Twycross R, Wilcock A. Palliative care formulary. 3rd ed. Oxford: Oxford University Press, 2007
4. Grape S, Schug SA, Lauer S, et al. Formulations offentanyl for the management of pain. Drugs 2010; 70 (1): 57-72
5. Madhav NV, Shakya AK, Shakya P, et al. Orotransmucosal drug delivery systems: a review. J Control Release 2009 Nov 16; 140 (1): 2-11
6. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991 Aug; 75 (2): 223-9
7. Darwish M, Kirby M, Robertson Jr P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol2007 Mar; 47 (3): 343-50 (Pubitemid 46294716)
8. Vasisht N, Gever LN, Tagarro I, et al. Formulation selection and pharmacokinetic comparison of fentanyl buccal so-luble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig 2009; 29 (10): 647-54
9. Vasisht N, Gever LN, Tagarro I, et al. Evaluation of the singleand multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J Clin Pharmacol 2010; 50 (7): 785-91
10. Vasisht N, Gever LN, Tagarro I, et al. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med 2010; 11 (7): 1017-23
11. Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010 Jun; 21 (6): 1308-14
12. Skinner C, Thompson E, Davies A. Clinical features. In: Davies A, editor. Cancer-related breakthrough (episodic) pain. Oxford: Oxford University Press, 2006
13. Data on file. Clinical study report FEN-202: an open-label, long-term treatment evaluation of the safety of BEMA™ Fentanyl use for breakthrough pain in cancer patients on chronic opioid therapy. BioDelivery Sciences International Inc., 2007
14. Zeppetella G. Is the recommended titration schedule for OTFC too conservative? Eur J Palliative Care 2005; 12 (Suppl.): 4-6
15. Data on file. Clinical study report FEN-110: an evaluation of the single dose pharmacokinetics of BEMA™ Fentanyl. Raleigh (NC): BioDelivery Sciences International Inc., 2007
16. Onsolis prescribing information. 2.1 Dose titration. Madrid: Meda Pharmaceuticals Inc., 2009